Diabetes Mellitus, Erectile Dysfunction, Vitamin D Deficiency
Conditions
Brief summary
males with diabetes complain impotence in the presence of low vitamin D deficiency. pharacmological treatment of low vitamin D levels is necessary but changing lifestyle by performing exercise is also important
Detailed description
forty diabetic men (type 2) who complain presence of low vitamin D and impotence will be divided to group number I and group number II. Both groups will be pharmacologically treated by administration of Cholecalciferol 200.000 I.U (will be taken every two weeks). this treatment will last for 12 weeks. Additionally, Group number I will perform treadmill walking (one hour walking) with moderate intensity. This walking will be performed three times per designed week for twelve weeks.
Interventions
BEHAVIORALexercise and vitamin D intake
twenty diabetic men (type 2) who complain presence of low vitamin D and impotence will be pharmacologically treated by administration of Cholecalciferol 200.000 I.U (will be taken every two weeks). this treatment will last for 12 weeks. Additionally, Group number I will perform treadmill walking (one hour walking) with moderate intensity. This walking will be performed three times per designed week for twelve weeks.
OTHERvitamin D intake
twenty diabetic men (type 2) who complain presence of low vitamin D and impotence will be pharmacologically treated by administration of Cholecalciferol 200.000 I.U (will be taken every two weeks). this treatment will last for 12 weeks.
Sponsors
Cairo University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
35 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
* diabetic men (forty) * type 2 diabetes * complaint of erectile dysfucntion (chronic complaint more than 24 months) * men with low vitamin D (deiciency in vitamin D)
Exclusion criteria
* cardiac patients * respiratory disease patients * renal disease * liver disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| international index of erectile function | it will be measured after 12 weeks | questionnaire used to assess impotence |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| glycated hemoglubin | It will be measured after 12 weeks | it will be used to assess blood glcuose |
| fasting blood glcuose | It will be measured after 12 weeks | it will be used to assess blood glcuose in serum |
| body mass index | It will be measured after 12 weeks | it will be measured on empty stomach and bladder |
| wasit circumference | it will be measured after 12 weeks | it will be measured at umbilicus level |
| high density lipoprotein | It will be measured after 12 weeks | it will be measured in serum |
| low density lipoprotein | It will be measured after 12 weeks | it will be measured in serum |
| triglycerides | It will be measured after 12 weeks | it will be assessed in serum |
| cholesterol | It will be measured after 12 weeks | it will be assessed in serum |
| 25-hydroxyvitamin D | It will be measured after 12 weeks | it will be assessed in serum as a metabolite of vitamin D |
Countries
Egypt
Contacts
CONTACTAli MA Ismail, lecturer
CONTACTAli mohamed, lecturer
PRINCIPAL_INVESTIGATORAli MA Ismail, lecturer
Cairo University
Outcome results
None listed